Jericho’s J-Test

A whole blood assay to assess individual patient responses to novel antiviral therapeutics.

There is no clinical assay for the reservoir.

─ RF Siliciano, July 2013 (Curr Opin HIV AIDS; 8(4): 318-325) p.322 second paragraph

While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Therefore, longer term and “curative” therapeutic approaches are being explored. Developing newer therapeutic strategies that can reduce or clear persistent, underlying sources of virus infection will require novel clinical diagnostic assays and tools. Such tools must comprehensively evaluate virologic, immunologic and safety parameters for individuals who may require personalized therapies.

Our results indicate that no single in vitro cell model alone is able to capture accurately the ex vivo response characteristics of latently infected T cells from patients.

─ CA Spina, Dec 2013 (PLoS Pathog.;9(12): e1003834) Abstract

The current gold standard, the Quantitative Viral Outgrowth Assay (QVOA) is expensive, labor intensive, highly variable, takes several weeks to complete and requires large volumes of blood.

Jericho Sciences is developing a clinically relevant, diagnostic assay for personalized clinical management of “curative” therapeutic strategies for HIV-1 infection. Our Patented technology assesses patient-specific responses across comparative conditions using multiparametric measures from the full peripheral blood immunologic compartment. Most other assays exclude cells other than CD4 T cells. Jericho’s assay more accurately reflects the natural environment of CD4 T cells.

How the J-Test Works

  1. Draw blood into prefilled collection tubes
  2. Incubate 2-3 days
  3. Collect supernatant and cells
  4. Measure virus production, provirus, cell phenotypes, soluble factors
  5. Correlate measures

Jericho’s J-Test Value Proposition

  • Clinically Relevant: Requires small volumes of blood
  • Patient-Specific: Internally-referenced
  • Short Turnaround Time: Results within 1 week
  • Multiparametric: Cellular, viral, and immunologic parameters
  • Primary Cells: Direct source and response to virus production
  • Supports Clinical Success: Enables identification of biomarkers